Recombinant Human IL9R Protein (Met1-Pro270), C-His tagged

• Cat.No.: IL9R-4293H
• Product Overview: Recombinant human IL9R (Met1-Pro270) fused with the C-terminal His tag was expressed in Mammalian cells.

Specification

• Source: Mammalian cells
• Species: Human
• Tag: His
• Form: Lyophilized powder/frozen liquid
• Molecular Mass: 29.7 kDa
• Protein length: Met1-Pro270
• Endotoxin: < 1.0 EU/μg of the protein as determined by the LAL method.
• Purity: >90% as determined by SDS-PAGE.
• Notes: For research use only.
• Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 centigrade for one week. Store at -20 to -80 centigrade for twelve months from the date of receipt.
• Storage Buffer: Supplied as solution form in PBS or lyophilized from PBS.
• Reconstitution: Reconstitute in sterile water for a stock solution.
• Shipping: They are shipped out with dry ice/blue ice unless customers require otherwise.

Gene Information

• Gene Name: IL9R interleukin 9 receptor [ Homo sapiens (human) ]
• Official Symbol: IL9R
• Synonyms: IL9R; interleukin 9 receptor; interleukin-9 receptor; CD129; IL-9R; IL-9 receptor
• Gene ID: 3581
• mRNA Refseq: NM_002186
• Protein Refseq: NP_002177
• MIM: 300007
• UniProt ID: Q01113

Reviews

05/10/2022

IL9R is very advanced and adopts the most environmentally friendly production process, which is worth vigorously promoting.

01/11/2022

The reproducibility of IL9R is very good, and the results are very consistent in each experiment or application, thanks to its high stability and reproducibility, which provides great convenience for follow-up studies.

02/27/2020

IL9R produced by them are widely used and suitable for various biological experiments.

Q&As

Can the treatment of cancer with IL9R improve the immune system of patients?

In pre-clinical trials, the IL9R significantly increased natural killer and CD4 + T cell levels in patients.

What somatic cell therapy-based data updates can recombinant IL9R be used for?

IL9R may play an important role in the treatment of central nervous system diseases and hematological diseases.

In which tumor therapies are recombinant IL9R most likely to be effective?

This needs to be further confirmed by large-scale clinical trials.

What techniques are used to study the relationship between IL9R and cancer?

This can be achieved through in vitro molecular cell techniques and carefully designed in vivo animal models.

Which diseases might be treated by recombinant IL9R?

There have been no large-scale clinical studies to prove which diseases the recombinant IL9R protein can treat.

Is the expression of IL9R in tumor cells correlated with patient prognosis?

Some studies have suggested that the expression of IL9R in tumor cells may be associated with patient prognosis.